KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Payables: 2018-2025

Historic Payables for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Sep 2025 value amounting to $2.2 million.

  • Aurinia Pharmaceuticals' Payables fell 96.10% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year decrease of 91.10%. This contributed to the annual value of $5.2 million for FY2024, which is 19.88% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Payables stood at $2.2 million, which was down 33.15% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Payables registered a high of $56.8 million during Q3 2024, and its lowest value of $2.2 million during Q3 2025.
  • Its 3-year average for Payables is $28.4 million, with a median of $36.0 million in 2023.
  • In the last 5 years, Aurinia Pharmaceuticals' Payables surged by 89.36% in 2021 and then crashed by 96.10% in 2025.
  • Aurinia Pharmaceuticals' Payables (Quarterly) stood at $34.9 million in 2021, then rose by 14.43% to $40.0 million in 2022, then slumped by 89.18% to $4.3 million in 2023, then rose by 19.88% to $5.2 million in 2024, then crashed by 96.10% to $2.2 million in 2025.
  • Its Payables stands at $2.2 million for Q3 2025, versus $3.3 million for Q2 2025 and $4.2 million for Q1 2025.